Trial · NCT05078879
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
NCT05078879, Phase 1, Completed, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency. Trials, record NCT05078879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05078879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
- NCT number
- NCT05078879
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 4 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
- Interventions
- Empagliflozin
- First posted
- 2021-10-15
- Last updated
- 2025-06-26
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute Neutrophil Count | End of Treatment at 12 months | ANC increase by \>500 cells/uL over baseline (measured at least 3x over 2 days) |
| Primary | Safety | End of Treatment at 12 months | No Grade 3/4 toxicities that require pause of the study drug. |
| Secondary | Neutrophil Function | End of Treatment at 12 months | Improved in vitro NADPH oxidase function, Staphylococcus aureus killing assay, and chemotaxis assay. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05078879
GET https://conductscience.org/api/trials/v1/NCT05078879/registered